Physician profile
Shelly Mathur
NPI 1831344530
$9,416.67
in general payments reported to CMS, 2019-2025
49 companies · $1,637 in 2025
The $1,637 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $830 · 2021: $1,649 · 2022: $1,692 · 2023: $1,811 · 2024: $979 · 2025: $1,637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,426.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,332.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $866.16 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $732.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $570.50 | 2019-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $563.48 | 2019-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $464.55 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $436.41 | 2019-2025 | |
| Abbott Laboratories | $404.33 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $393.34 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $375.89 | 2019-2025 | Unithroid |
| Abbvie INC. | $361.26 | 2019-2025 | |
| Ibsa Pharma INC. | $345.24 | 2019-2025 | Tirosint, Licart, Tirosint |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.77 | 2020-2025 | Jardiance, Tradjenta |
| Tandem Diabetes Care, INC. | $202.17 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Avvisto Therapeutics, LLC | $156.97 | 2025 | Cycloset |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $155.09 | 2021-2023 | Tepezza |
| Corcept Therapeutics | $147.23 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $127.95 | 2021-2024 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $125.40 | 2021-2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $123.52 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.00 | 2021-2024 | Cycloset |
| Bayer Healthcare Pharmaceuticals INC. | $122.33 | 2021-2022 | |
| Insulet Corporation | $118.60 | 2019-2025 | Omnipod |
| Antares Pharma, INC. | $107.00 | 2020-2023 | Nocdurna, Tlando, Xyosted |
| Ascendis Pharma Endocrinology INC | $96.39 | 2023-2025 | Yorvipath |
| Cequr Corporation | $88.00 | 2022-2025 | Cequr Simplicity |
| Sequel Med Tech, LLC | $60.67 | 2025 | Twiist |
| Beta Bionics, INC. | $47.40 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Merck Sharp & Dohme LLC | $38.88 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $33.33 | 2020-2022 | |
| Madrigal Pharmaceuticals | $32.38 | 2025 | Rezdiffra |
| Currax Pharmaceuticals LLC | $30.63 | 2023-2024 | Contrave, Nexlizet, Nexletol |
| Kowa Pharmaceuticals America, INC. | $29.24 | 2021-2023 | Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $26.09 | 2021 | |
| Kyowa Kirin, INC. | $25.00 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $24.82 | 2022 | |
| Esperion Therapeutics, INC. | $23.54 | 2021-2022 | |
| Inogen, INC. | $23.40 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Halozyme INC | $23.39 | 2023 | |
| Shire North American Group INC | $22.26 | 2019 | |
| Companion Medical, INC. | $21.69 | 2020 | |
| Alvogen INC | $21.46 | 2023 | Teriparatide |
| Recordati_rare_diseases_inc. | $21.43 | 2023 | Signifor Lar, Isturisa |
| Medtronic, INC. | $19.53 | 2022 | |
| Amarin Pharma, INC. | $17.27 | 2021 | |
| Tolmar, INC. | $15.74 | 2023 | |
| Clarus Therapeutics INC. | $15.63 | 2021 | |
| Amryt Pharma Holdings LTD | $13.72 | 2023 | Mycapssa |
| Janssen Pharmaceuticals, INC | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.